Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)

Mark Gurney¹, Abhishek A Mangaonkar¹, Terra Lasho¹, Christy Finke¹, Aref Al-Kali¹, Naseema Gangat¹, Mithun V Shah¹, Hassan B Alkhateeb¹, Ayalew Tefferi¹, David Sallman², Zhuoer Xie², David Viswanatha³, Kaaren Reichard³, Najla Al Ali², Rami Komrokji², Eric Padron⁴, Mrinal M Patnaik⁵

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. eric.padron@moffitt.org.
⁵ Division of Hematology, Mayo Clinic, Rochester, MN, USA. patnaik.mrinal@mayo.edu.

PMID: 37422593
DOI: 10.1038/s41375-023-01964-3

Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)

Mark Gurney et al. Leukemia. 2023 Aug.

. 2023 Aug;37(8):1753-1756.

doi: 10.1038/s41375-023-01964-3. Epub 2023 Jul 8.

Authors

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. eric.padron@moffitt.org.
⁵ Division of Hematology, Mayo Clinic, Rochester, MN, USA. patnaik.mrinal@mayo.edu.

PMID: 37422593
DOI: 10.1038/s41375-023-01964-3

No abstract available

PubMed Disclaimer

Cited by

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Bataller A, Gener-Ricos G, Almanza-Huante E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bataller A, et al. Blood Adv. 2024 Jun 11;8(11):2695-2706. doi: 10.1182/bloodadvances.2024012565. Blood Adv. 2024. PMID: 38513082 Free PMC article.
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2024 Jun;99(6):1142-1165. doi: 10.1002/ajh.27271. Epub 2024 Mar 7. Am J Hematol. 2024. PMID: 38450850 Free PMC article. Review.
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.
Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes J, Azaceta G, Ibáñez M, Chen T, Notario C, Amer N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo J, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Blood Adv. 2025 Jan 14;9(1):39-53. doi: 10.1182/bloodadvances.2024013648. Blood Adv. 2025. PMID: 39388660 Free PMC article.
Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL).
Grass M, Geissler K. Grass M, et al. Wien Med Wochenschr. 2025 Mar 5. doi: 10.1007/s10354-025-01072-0. Online ahead of print. Wien Med Wochenschr. 2025. PMID: 40042734 English.
Allogeneic Transplant for CMML.
Gagelmann N, Desai N. Gagelmann N, et al. Curr Hematol Malig Rep. 2025 Aug 11;20(1):10. doi: 10.1007/s11899-025-00754-1. Curr Hematol Malig Rep. 2025. PMID: 40788558 Free PMC article. Review.

See all "Cited by" articles

References

1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. - DOI - PubMed - PMC
1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. - DOI - PubMed
1. Cumbo C, Tota G, Anelli L, Zagaria A, Specchia G, Albano F. TP53 in myelodysplastic syndromes: recent biological and clinical findings. Int J Mol Sci. 2020;21. https://doi.org/10.3390/IJMS21103432 .
1. Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31:705–11. - DOI - PubMed
1. Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, et al. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023;108:150–60. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)

Affiliations

Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous